Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
This article was originally published in The Pink Sheet Daily
Deal continues Abbott’s strategy over the last few years of becoming more focused on its pharmaceuticals business.
You may also be interested in...
Candidates would be competitors to Pfizer's Lipitor/torcetrapib combination.
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.